Anti-tumour efficacy of IL-1 and IL-2.
The potential value of RIL-1 and RIL-2 for local immunotherapy of cancer was compared in the experimental model of MC-induced sarcomas growing in syngeneic (B10) mice. Highly purified recombinant human RIL-1 (Hoffmann-La Roche) and RIL-2 (Amersham) were administered s.c. into the area of lymph nodes draining the growing tumour. Within the dose range examined, RIL-2 was capable of inducing inhibition of tumour growth or complete regression of tumours and the cure of the majority of treated mice. In contrast, RIL-1 could neither inhibit tumour growth nor potentiate the tumour-inhibitory effect of RIL-2.